0 322

Cited 11 times in

TP53 Mutation Status of Tubo-ovarian and Peritoneal High-grade Serous Carcinoma with a Wild-type p53 Immunostaining Pattern

Authors
 KIYONG NA  ;  JI-YOUN SUNG  ;  HYUN-SOO KIM 
Citation
 ANTICANCER RESEARCH, Vol.37(12) : 6697-6703, 2017 
Journal Title
ANTICANCER RESEARCH
ISSN
 0250-7005 
Issue Date
2017
MeSH
Aged ; Base Sequence ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cystadenocarcinoma, Serous/genetics* ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; DNA Mutational Analysis/methods ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; Mutation* ; Ovarian Neoplasms/genetics* ; Ovarian Neoplasms/metabolism ; Ovarian Neoplasms/pathology ; Peritoneum/metabolism ; Peritoneum/pathology ; Sequence Homology, Nucleic Acid ; Tumor Suppressor Protein p53/genetics* ; Tumor Suppressor Protein p53/metabolism
Keywords
Ovary ; TP53 mutation ; high-grade serous carcinoma ; immunohistochemistry ; p53 ; sequencing
Abstract
BACKGROUND/AIM: Diffuse and strong nuclear p53 immunoreactivity and a complete lack of p53 expression are regarded as indicative of missense and nonsense mutations, respectively, of the TP53 gene. Tubo-ovarian and peritoneal high-grade serous carcinoma (HGSC) is characterized by aberrant p53 expression induced by a TP53 mutation. However, our experience with some HGSC cases with a wild-type p53 immunostaining pattern led us to comprehensively review previous cases and investigate the TP53 mutational status of the exceptional cases.

MATERIALS AND METHODS: We analyzed the immunophenotype of 153 cases of HGSC and performed TP53 gene sequencing analysis in those with a wild-type p53 immunostaining pattern.

RESULTS: Immunostaining revealed that 109 (71.3%) cases displayed diffuse and strong p53 expression (missense mutation pattern), while 39 (25.5%) had no p53 expression (nonsense mutation pattern). The remaining five cases of HGSC showed a wild-type p53 immunostaining pattern. Direct sequencing analysis revealed that three of these cases harbored nonsense TP53 mutations and two had novel splice site deletions.

CONCLUSION: TP53 mutation is almost invariably present in HGSC, and p53 immunostaining can be used as a surrogate marker of TP53 mutation. In cases with a wild-type p53 immunostaining pattern, direct sequencing for TP53 mutational status can be helpful to confirm the presence of a TP53 mutation.
Full Text
http://ar.iiarjournals.org/content/37/12/6697.long
DOI
10.21873/anticanres.12128
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Pathology (병리학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hyun-Soo(김현수)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/161462
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links